View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
May 7, 2021

IVD companies seek M&As to avoid Covid cliff

In-vitro diagnostic (IVD) companies are reporting significant revenue increases in the first quarter of the year, largely due to the continued sales of Covid-19 tests. Despite these strong first-quarter reported revenues, Covid-19 testing sales are expected to quickly decline in the second half of the year as many countries around the world steadily roll out Covid-19 vaccines.

By GlobalData Healthcare

In-vitro diagnostic (IVD) companies are reporting significant revenue increases in the first quarter of the year, largely due to the continued sales of Covid-19 tests. Despite these strong first-quarter reported revenues, Covid-19 testing sales are expected to quickly decline in the second half of the year as many countries around the world steadily roll out Covid-19 vaccines.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

According to Our World in Data, Israel currently leads with the largest share of people who have received at least one dose of a Covid-19 vaccine, at 62.5%. This is followed by the UK at 51.1%, the US at 44.2%, Germany at 29.3%, France at 23.7% and India at 9.3%. The expected decline in Covid-19 testing is being referred to in the biotech industry as the ‘Covid cliff’. IVD companies are preparing for a reduction in sales revenues for Covid-19 tests ranging anywhere from a steep drop-off to a more gradual downturn.

Sales related to Covid-19 tests are just one part of the picture. The Covid-19 pandemic dramatically altered the biotech landscape last year with increases in funding to biotech, most of which were Covid-related, and many IVD companies benefited from this increased funding. An unprecedented number of IVD companies entered the Covid-19 testing space, developing and launching products in record time and numbers. Clinical trial volumes also saw a significant increase last year.

In preparation for the Covid cliff, three major IVD companies have turned to mergers and acquisitions (M&As) to shore up their diagnostic testing portfolios. In March, Roche signed a merger agreement with GenMark Diagnostics to access GenMark’s molecular diagnostic panel tests, which are designed to detect multiple pathogens from a single patient sample. Multiplex testing is currently gaining preference as it allows physicians to quickly diagnose a patient or rule out multiple common pathogens.

In April, Hologic made a similar move by acquiring Mobidiag, which also offers multiplex testing. Hologic said the acquisition will enable the company to enter the acute care test market, which is projected to grow after the pandemic ends. In the same month, DiaSorin agreed to buy its US rival, Luminex, to boost its core molecular business and offset the expected drop in demand for Covid-19 tests in the second half of the year. Roche, Hologic and DiaSorin are all strong players in the Covid-19 testing space, and these M&As indicate that the market is shifting its attention to prepare for a return to a post-pandemic world.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network